Mesoblast Shares Rise As Remestemcel-L Cuts Mortality In Patients Below 65 Years With COVID-19 Related Respiratory Distress Mesoblast Limited (NASDAQ: MESO ) has announced 60-day results from the randomized controlled trial of remestemcel-L in COVID-19 patients with moderate|severe acute respiratory distress syndrome (ARDS), which had been halted after the third interim analysis, as previously announced. The trial enrolled 222 mechanically ventilated COVID-19 patients. Remestemcel-L reduced mortality by 46% through day 60 in the pre-specified population of 123 treated patients under age … Full story available on Benzinga.com